InocuJect's device is unique in exploiting the known biophysics and biology of the dermis to achieve very high immunization efficiency for many types of antigens, including coded plasmid DNA and mRNA vaccines. It will achieve this with 100 + better immunization efficiency than with traditional needles and syringes.
The technology is based on a prototype developed by Dr. Kobinger in collaboration with the engineering department at the University of Laval in Quebec City. InocuJect acquired this technology and the original IP, and has developed new IP and a working electromechanical prototype.
The design has been based on an initial, purely mechanical, proof-of-concept device that was then refined through a rigorous process of simulation and engineering calculations. This device is now ready for testing by Dr. Kobinger at the Galveston National Laboratory (GNL). Testing will also be done by Dr. John Bell at Ottawa Hospital Research Institute.
InocuJect's vaccine delivery platform has a number of advantages over traditional needle and syringe injections, including:
InocuJect was founded in December 2020 to commercialize 5 years of research by Dr. Gary Kobinger. His research has recently been published in Nature Vaccine.
InocuJect will be both a veterinary and human dermal vaccine delivery platform. The veterinary device will be an easy to use, self-actuated, electromechanical, battery powered multi-use device. Each device will be optimized for specific animal vaccination programs.
The human dermal vaccine device delivery platform is a single-use delivery system that harnesses the natural immune response system in the skin to deliver vaccines in the most efficient way possible. The products will be an easy to use device platform designed to improve assisted/professional administration. We will have proprietary, optimized devices for individual vaccine campaigns whose path to market will be drug device combination products.
InocuJect will also eventually enable guided (self-administered) vaccines. The products will target both civilian and military applications and eventually pave the way for self-vaccination in non-clinical settings (home or office).
InocuJect's team of co-founders has global regulatory expertise between Dr. Kobinger and multiple world-class engineers. InocuJect also has a stellar Scientific Advisory Board and credible Business Advisors.
Interested in learning more about InocuJect? Sign up below to stay in the loop and be the first to hear about our upcoming white paper.